Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 5.6%

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was down 5.6% on Monday . The company traded as low as $7.91 and last traded at $7.94. Approximately 2,262,832 shares traded hands during trading, a decline of 66% from the average daily volume of 6,719,053 shares. The stock had previously closed at $8.41.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on RXRX shares. TD Cowen started coverage on Recursion Pharmaceuticals in a research note on Friday, January 26th. They set a “market perform” rating for the company. KeyCorp lifted their price objective on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research note on Monday, March 4th. Finally, Needham & Company LLC restated a “buy” rating and set a $17.00 target price on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 9th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $12.75.

Recursion Pharmaceuticals Trading Up 0.7 %

The company has a fifty day moving average price of $10.87 and a two-hundred day moving average price of $9.11.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings results on Tuesday, February 27th. The company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.46) by $0.06. The firm had revenue of $10.89 million for the quarter, compared to analyst estimates of $12.37 million. Recursion Pharmaceuticals had a negative net margin of 735.99% and a negative return on equity of 72.88%. Research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.63 earnings per share for the current year.

Insider Activity

In other Recursion Pharmaceuticals news, COO Tina Marriott Larson sold 8,000 shares of the business’s stock in a transaction that occurred on Thursday, January 25th. The stock was sold at an average price of $10.35, for a total value of $82,800.00. Following the sale, the chief operating officer now owns 414,548 shares of the company’s stock, valued at $4,290,571.80. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 20,054 shares of the business’s stock in a transaction on Tuesday, January 23rd. The shares were sold at an average price of $10.58, for a total value of $212,171.32. Following the completion of the transaction, the director now owns 7,324,364 shares in the company, valued at $77,491,771.12. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, COO Tina Marriott Larson sold 8,000 shares of the business’s stock in a transaction on Thursday, January 25th. The stock was sold at an average price of $10.35, for a total transaction of $82,800.00. Following the transaction, the chief operating officer now owns 414,548 shares of the company’s stock, valued at approximately $4,290,571.80. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 341,701 shares of company stock valued at $3,568,471. 19.96% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Recursion Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the company. Ameritas Investment Partners Inc. boosted its stake in Recursion Pharmaceuticals by 11.1% in the second quarter. Ameritas Investment Partners Inc. now owns 11,270 shares of the company’s stock valued at $84,000 after acquiring an additional 1,129 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Recursion Pharmaceuticals by 2.7% in the fourth quarter. The Manufacturers Life Insurance Company now owns 55,778 shares of the company’s stock valued at $430,000 after buying an additional 1,458 shares during the last quarter. National Bank of Canada FI raised its stake in Recursion Pharmaceuticals by 90.9% during the fourth quarter. National Bank of Canada FI now owns 3,150 shares of the company’s stock worth $31,000 after purchasing an additional 1,500 shares during the period. Vident Investment Advisory LLC raised its stake in Recursion Pharmaceuticals by 16.6% during the fourth quarter. Vident Investment Advisory LLC now owns 13,581 shares of the company’s stock worth $105,000 after purchasing an additional 1,934 shares during the period. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its stake in Recursion Pharmaceuticals by 6.2% during the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 33,002 shares of the company’s stock worth $252,000 after purchasing an additional 1,938 shares during the period. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.